GERN Stock Analysis: Buy, Sell, or Hold?
GERN - Geron Corp
$1.36
0.09 (7.09%)
▲
5d:
-0.73%
30d:
+16.24%
90d:
-18.07%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 7.6/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GERN shows positive signals but monitor for confirmation. Market pricing in 1.0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: GERN shows positive signals but monitor for confirmation. Market pricing in 1.0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.36, which is considered extended relative to its 30-day fair value range of $1.15 to $1.32. The stock's valuation (Forward PE: 20.9) is in line with its historical norms (20.3). At these levels, the market is pricing in 1.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a strong downtrend. Immediate support is located at $1.23, while resistance sits at $1.47. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: GERN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+150.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GERN is in a strong downtrend. Immediate support is located at $1.23, while resistance sits at $1.47. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: GERN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+150.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.15 -
$1.32
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.1%)
- BULLISH: Trading 150.0% below Wall St target ($3.40)
- NEUTRAL: Market pricing in 1.0% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$1.15 -
$1.32
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.23
Resistance Level
$1.47
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.92
Wall Street Target
$3.40
(+150.0%)
Revenue Growth (YoY)
30.9%
Profit Margin
-34.3%
Valuation Premium vs History
+1.0% premium
PE vs Historical
20.9 vs 20.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$1.37
(+1%)
2-Year Target
$1.39
(+2%)
3-Year Target
$1.40
(+3%)
3-Yr Target (if PE normalizes)
(PE: 21→20)
PE COMPRESSION
$1.36
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 02, 2026 10:42 PM ET
Data refreshes hourly during market hours. Next update: 11:42 PM
Data refreshes hourly during market hours. Next update: 11:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
